checkAd
    Startseite > Aktien > Ocugen > Nachrichten
    Ocugen Aktie
    1,4480
     
    EUR
    -1,96 %
    -0,0290 EUR
    Letzter Kurs 19:00:26 Tradegate
    1,4520
     
    EUR
    10.000 STK
    Geldkurs 19:48:34
    1,4750
     
    EUR
    10.000 STK
    Briefkurs 19:48:34
    ISIN: US67577C1053 · WKN: A2PSZH · SYM: 2H51 · USA

    Neueste Nachrichten

    OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN
    16:41 Uhr · Business Wire (engl.) · Ocugen
    DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
    16:20 Uhr · Business Wire (engl.) · Ocugen
    MONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
    07.06.24 · Business Wire (engl.) · Ocugen
    Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
    31.05.24 · globenewswire · Ocugen
    Ocugen to Present at BIO International Convention 2024
    29.05.24 · globenewswire · Ocugen
    Ocugen Set to Join Russell 3000 Index Effective June 28, 2024
    28.05.24 · globenewswire · Ocugen
    The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
    27.05.24 · Business Wire (engl.) · Ocugen
    Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ocugen, Inc. (OCGN)
    22.05.24 · Business Wire (engl.) · Ocugen
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
    22.05.24 · Business Wire (engl.) · Ocugen
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Ocugen, Inc. (OCGN) Investors
    22.05.24 · Business Wire (engl.) · Ocugen
    Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
    20.05.24 · globenewswire · Ocugen
    Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
    15.05.24 · globenewswire · Ocugen